Background {#Sec1}
==========

In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. This article discusses the specific problems of managing people with diabetes and COVID-19 in ICU.

In the recent Corona Virus Disease 2019 (COVID-19) pandemic people with diabetes are paying a very high price.

Probably they are not exposed to higher risk of being infected, however, in the case, particularly when the metabolic control is not sufficient, they are more prone to serious complications and to die \[[@CR1]--[@CR5]\]. The rates of severe disease are significantly higher in patients with diabetes compared with non-diabetes (34.6% vs. 14.2) \[[@CR5]\]. Similarly, type 2 diabetic patients have higher rates of need for Intensive Care Unit (ICU), (37.0% vs. 26.7%) \[[@CR5]\].

It is well recognized that the management of people with diabetes in an ICU is particularly challenging \[[@CR6]\]. To this situation we have to add that diabetes is very often accompanied by co-morbidities, such as cardiovascular disease, hypertension and obesity, which by themselves worsen the prognosis of people with COVID-19 \[[@CR1]--[@CR5]\]. Moreover, there are also several other conditions (described in the course of the article), commonly present in diabetes, which can expose people with diabetes and COVID-19 at high risk for complications. It seems, therefore, quite clear that people with diabetes may have a particular profile/needs when hospitalized in ICU for the COVID-19. In this article we seek to discuss the specific issues to which people with diabetes can be exposed in ICU when having the COVID-19.

Glycemic control {#Sec2}
================

It is well recognized that an optimal glycemic control during the stay in ICU can improve the prognosis \[[@CR7]\]. However, the optimal glycemic control, particularly in ICU involves today several aspects. Unfortunately, it is not surprising that patients suffering from COVID-19 with hyperglycemia may have a higher risk and a poorer outcome compared with those with euglycemia \[[@CR8]\]. In particular, very recent reports from the USA have shown that uncontrolled glycemia is exposing people with diabetes and COVID-19 at a very high risk to develop serious complications or to die \[[@CR9], [@CR10]\].

Evidence shows that in ICU the more time the patients spend in the normal range of glycemia, the better is their prognosis \[[@CR11], [@CR12]\]. This is also the case of COVID-19. It has been reported that a tight glycemic control with insulin infusion had a lower risk of severe disease than patients without insulin infusion \[[@CR13]\].

This aspect might be of immediate understanding, however, it also implies to recognize why acute peaks of glycemia, episodes of hypoglycemia or, even worse, the exposure of the patients to huge glucose variability during the stay in ICU are all rather deleterious. Acute hyperglycemia produces oxidative stress followed by an enormous production of inflammatory cytokines \[[@CR14]\], a situation that obviously must be avoided during any stay in ICU, but particularly during the stay for COVID-19. It is well known that during this disease a massive cytokines storm can occur, with severely damaging effects \[[@CR15]\]. Hypoglycemia can produce the same effects as acute hyperglycemia and can expose directly people to the risk of dying \[[@CR16], [@CR17]\]. Furthermore, how hypoglycemia is recovered might be dangerous: hyperglycemia post-hypoglycemia is also an issue, leading to an enhancement of inflammation \[[@CR18]\].

Finally, there are plenty of reports in the literature that glucose variability is producing a worsening of the prognosis in ICU \[[@CR16], [@CR19]--[@CR22]\] even when glucose is kept in normal range \[[@CR22]\]. So it seems advisable that glucose variability should be avoided. Glucose variability also induces the generation of the oxidative stress and the release of inflammatory cytokines \[[@CR23]\].

Is the issue of glycemic control also of importance for people with diabetes and COVID-19? It seems, unfortunately, the case, according to reports on how glycemia was managed in several situations during this pandemic \[[@CR24], [@CR25]\]. When facing high glucose levels due to severe infection per se, it is often required that patients are switched to insulin, with some concerns that insulin treatment might not always be safely managed in such situations, unless insulin is administered intravenously via an exactly dosing perfusion device to avoid subcutaneous absorption irregularities in critically ill patients \[[@CR26], [@CR27]\]. Hyperglycemia is common in the Intensive Care Unit (ICU) both in patients with and without a previous diagnosis of diabetes \[[@CR28]\]. The optimal glucose range in the ICU population is still a matter of debate. Given the risk of hypoglycemia associated with intensive insulin therapy, current recommendations include treating hyperglycemia after two consecutive glucose \> 180 mg/dL with target levels of 140--180 mg/dL for most patients \[[@CR28]\]. The optimal method of sampling glucose and delivery of insulin in critically ill patients remains elusive. While point of care glucose meters are not consistently accurate and have to be used with caution, continuous glucose monitoring (CGM) is not standard of care and is not yet generally recommended for inpatient use. The advent of new technologies, such as electronic glucose management, CGM, and closed-loop systems, promises to improve inpatient glycemic control in the critically ill with lower rates of hypoglycemia \[[@CR28]\].

The issue of optimal glycemic control is certainly even more complicated during the management of COVID-19 because high doses of glucocorticoids are often used \[[@CR29]\].

Glucocorticoids improve the prognosis of COVID-19 but, of course, induce or worsen hyperglycemia \[[@CR30]\]. In the case keeping normal glycemia may be very challenging \[[@CR30]\].

Another challenge in managing glycemia during the stay in ICU, particularly during the early phase, is the background anti-hyperglycemia therapy. While for several therapies, such as dipeptidyl-peptidase 4 inhibitors (DPP4 inhibitors), sodium-glucose-transporter-2 inhibitors (SGLT-2 inhibitors), pioglitazone, alpha-glucosidase inhibitors, metformin and short-acting Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RA) (exenatide and lixisenatide) their action is only shortly enduring after they are stopped, this cannot be the case for long-acting insulins but particularly for the long-acting GLP-1RA (dulaglutide, exenatide LA, liraglutide and semaglutide) \[[@CR31]\]. Their action will add to that of insulin used during the treatment in ICU and must be considered in choosing the insulin dose. On the other hand, many of them show an anti-inflammatory activity, which could be quite helpful during COVID-19 \[[@CR32]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Possible issues in the management of people with diabetes and COVID-19 in ICU. Several issues are present during the management of people with diabetes and COVID-19 in ICU. Tight glycemic control, avoiding hypoglycemia and glucose variability improves the prognosis. This goal, to be achieved, needs insulin infusion and continuous glucose monitoring (CGM). \*Moreover, the achievement of tight glucose control may be influenced by the background anti-hyperglycemic therapy and by the concomitant therapy with hydroxychloroquine (risk of hypoglycemia) or corticosteroids (inducing hyperglycemia). \*\*The evaluation of the meaning of several biomarkers related to the risk of cardiovascular complications, thrombosis and inflammation must be careful, because many of them are already altered by diabetes itself. There is no contraindication, however, to the use of ACEi or ARBS to control blood pressure. *ACEi* angiotensin-converting-enzyme inhibitors, *ARBs* angiotensin-receptor-blockers, *CV* cardio-vascular, *CGM* continuous glucose monitoring, *CRP* C-reactive protein, *Hs*-*Troponin* High-sensitive troponin, *ICU* Intensive Care Unit, *IL*-*6* interleukin-6, *NT*-*proBNP* N-Terminal-pro-Brain Natriuretic-Peptide

Another rising problem might be the concomitant use of hydroxychloroquine that, even it is controversial \[[@CR33]\], sometimes is used for preventing the effect of the "Severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) \[[@CR34]\]. Hydroxychloroquine has a proven hypoglycemic effect, therefore also in this case the insulin treatment must be very carefully managed in order to avoid episodes of hypoglycemia \[[@CR35]\]. Intriguingly, there is also evidence that optimal Covid-19 infection management with Tocilizumab is not achieved during hyperglycemia in both diabetic and non-diabetic patients \[[@CR36]\].

Increased attention is needed regarding the proper hydration of the diabetic patient with COVID-19 in the ICU \[[@CR37]\]. Hyperhydration can induce the onset of life-threatening pulmonary oedema due to the severity of lung damage during corona infection. Serum K levels are equally important, with a major risk of hypokalaemia, frequently associated with COVID-19, possibly due to hyperaldosteronism caused by elevated angiotensin 2 \[[@CR37]\]. Insulin treatment may worsen hypokalaemia if not corrected in time \[[@CR38]\].

Hypertension {#Sec3}
============

Diabetes is very often accompanied by hypertension \[[@CR39]\]. Fortunately, the issue of the possible role of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers in favoring the penetration of the SARS-CoV-2, due to the increasing receptor for the virus "Angiotensin-Converting-Enzyme-2" (ACE2), seems to be over \[[@CR40]\]. New specific data coming from people with the COVID-19, are certainly reassuring on this point \[[@CR41], [@CR42]\]. In the CORONADO study, which included 1317 patients with diabetes, neither hypertension nor treatment by renin--angiotensin--aldosterone system blockers were associated with a worse prognosis \[[@CR43]\]. Anyhow, the control of blood pressure remains an important point in the management of people in ICU and of course this particularly applies to people with diabetes.

The issue of the evaluation of biomarkers meaning in diabetes {#Sec4}
=============================================================

Several biomarkers have been suggested to be helpful in stratification of the risk during the COVID-19. Their value as helpful tools in the case of COVID-19 in people with diabetes needs a careful evaluation.

Biomarkers of cardiovascular disease and heart failure {#Sec5}
------------------------------------------------------

COVID-19 can cause serious acute cardiovascular events \[[@CR44]\]. Moreover, people with a previous cardiovascular disease are more prone to a worse prognosis if affected by SARS-CoV-2 \[[@CR1]--[@CR5]\]. A pre-existing cardiovascular disease very often accompanies diabetes, therefore, people with diabetes also for this reason may be exposed to a more serious complication when having the COVID-19. Furthermore, a large proportion of people with diabetes has asymptomatic coronary artery disease \[[@CR45], [@CR46]\] which can increase the risk of acute coronary syndrome, heart failure and arrhythmia during the COVID-19 due to proinflammatory process, hypercoagulability and sympathetic stimulation. QT interval is also often increased in people with diabetes, as a consequence of cardiac autonomic neuropathy \[[@CR47], [@CR48]\]. QT interval may be further lengthened by hypoglycemia and by drugs used during the COVID-19 and by hypokalemia and needs to be carefully monitored.

Hs-troponin has been suggested for monitoring the risk of myocardial infarction during the COVID-19 \[[@CR49], [@CR50]\]. However, in the case of diabetes, increased levels of hs-troponin have been reported \[[@CR47]\], as signal of an existing chronic heart damage, therefore its use for monitoring heart risk in diabetes during COVID-19 deserves some caution.

The situation is not different for heart failure, which again, has been described as a serious complication of COVID-19 \[[@CR49], [@CR50]\]. The measurement of the "N-Terminal-pro-Brain Natriuretic-Peptide" (NT-proBNP) to define the risk for heart failure in COVID-19 has been suggested \[[@CR48]--[@CR50]\]. However, plasma NT-proBNP level in a patient with COVID-19 must be seen as a marker of both the presence and extent of pre-existing cardiac disease and the acute haemodynamic stress related to COVID-19. As for hs-troponin, increased levels of NT-proBNP have been often reported in diabetes \[[@CR51], [@CR52]\]. According to various studies, an asymptomatic heart failure can be present in up to more than 50% of people with diabetes \[[@CR51]--[@CR53]\]. This condition is characterized by an increase of plasma NT-proBNP. So, again, the usefulness of a marker, in this case the NT-proBNP, needs a careful evaluation in the presence of diabetes and COVID-19.

Thrombosis biomarkers {#Sec6}
---------------------

Thrombosis has been found to occur very often during the COVID-19 and it is one of the most serious complications \[[@CR54]\]. The measurement of D-dimer is very useful in the prediction of the risk for a thrombotic event and its evaluation has been suggested regarding the management of COVID-19 patients \[[@CR55], [@CR56]\].

The situation in diabetes looks more complicated. D-dimer is often elevated in diabetes \[[@CR57], [@CR58]\]. It is just the index of increased thrombophilia, which is highly prevalent in diabetes \[[@CR59]\]. The thrombophilia in diabetes is related to an imbalance between thrombosis and fibrinolysis \[[@CR59]\]. This status suggests in one side that the evaluation of the thrombotic status in diabetes during the admission in ICU using the D-dimer should be very careful, but at the same time that an anticoagulation could be very helpful.

In this context the role of hyperglycemia also deserves attention. An acute increase of glycemia may activate thrombin formation \[[@CR60]\], convincingly through the glycation of the antithrombin III, a phenomenon that can be reversed by a fast control of hyperglycemia or by heparin \[[@CR61]\]. Heparin administration is largely suggested in the case of COVID-19, so it seems true that there is further reason for its use in the presence of diabetes \[[@CR50]\]. Finally, it has been recently reported that glucose variability may increase the platelet reactivity \[[@CR62]\]. Therefore, regarding the risk of thrombosis, there are good reasons to keep glycemia under a strict control, in association with anticoagulation.

Inflammation biomarkers {#Sec7}
-----------------------

Markers of inflammation, particularly C-reactive-protein and interleukin-6 have also been suggested as tools for monitoring the severity of the COVID-19 \[[@CR50], [@CR55]\]. Again diabetes has a particular situation. Low-grade inflammation is present in this disease \[[@CR63]\], therefore, as for thrombosis and heart failure, the significance of altered values of these markers needs a careful evaluation in people with diabetes and COVID-19. Furthermore, as reported above, an acute increase of glycemia as well as glucose variability are accompanied by an increased production of cytokines \[[@CR64], [@CR65]\], an effect that must be avoided in the COVID-19.

Lipids and statin use {#Sec8}
=====================

Most of diabetic patients are routinely on lipid-lowering treatment, in particular on statins in accordance with the current diabetes and cardiovascular disease guidelines \[[@CR66]\]. Statins have well-known anti-inflammatory effects and improve endothelial function, which may be protective against cardiovascular complications during COVID-19. However, through various mechanisms statins may enhance compensatory immune signals \[[@CR67]\]. In addition, similar to renin--angiotensin--aldosterone system blockers, experimental studies showed that statins also augment the ACE2 receptor expression \[[@CR68]\] and might thus facilitate the penetration of SARS-CoV-2 into the cells. Whether statins may be beneficial or harmful during virus-induced acute respiratory distress syndrome is controversial \[[@CR69], [@CR70]\]. Further investigations are urgently required to clarify the interplay of these complex mechanisms with the new coronaviruses. In addition statins may cause myotoxicity. A markedly increase in creatine kinase may be observed in some patients with COVID-19 \[[@CR1]\].

The benefit of statins in cardiovascular prevention is well established in people with diabetes. In this context there is no evidence for withdrawing statins during COVID-19. However creatin kinase should be carefully monitored and, if increased, statin therapy should be temporarily withheld in order to avoid rhabdomyolysis.

Type 1 diabetes {#Sec9}
===============

Probably it is not well recognized that all we have reported above, which is true for type 2 diabetes, applies also and particularly and more seriously to type 1 diabetes \[[@CR71], [@CR72]\]. Type 1 diabetes has the same, albeit not more than type 2 diabetes, risk for cardiovascular events \[[@CR71]\]. Moreover, it is important to note that many old people may have today type 1 diabetes. Data are reassuring, showing that people with type 1 diabetes are not more exposed to SARS-COV-2 infection \[[@CR73]\] nor to more severe outcomes compared to patients with type 2 diabetes \[[@CR43]\]. However, type 1 diabetes is more complicated to manage and probably deserves a special attention when admitted to ICU for COVID-19.

Conclusions {#Sec10}
===========

Managing people with diabetes in any acute setting is always very difficult. COVID-19 has a very severe prognosis for people with diabetes and evidence shows that a tight glucose control could be very helpful. In the case of COVID-19 people with diabetes are more exposed to cardiovascular complications, which may be more challenging to manage \[[@CR74], [@CR75]\].

The usefulness of several biomarkers suggested for evaluating/monitoring the severity of the disease might be less evident and their use needs a careful evaluation in the case of diabetes.

Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act.
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